BIIB vs BMY: fair value comparison
Biogen Inc. and Bristol-Myers Squibb Company · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our ranking by discount to fair value.
| BIIB | BMY | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $225.71 | $59.12 |
| 12-month range | $147.86–$235.35 | $42.60–$68.09 |
| Rank by discount to fair value | #73 of 108 Healthcare | #72 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Low | High |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BIIB fair value analysis · BMY fair value analysis